➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
Harvard Business School
Dow
Johnson and Johnson

Last Updated: April 22, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PANITUMUMAB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for panitumumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00089635 ABX-EGF (Panitumumab) Monotherapy in Subjects With Metastatic Colorectal Cancer Completed Amgen Phase 2 2004-08-01 The purpose of this study is to determine that ABX-EGF (panitumumab) will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.
NCT00091806 Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors Completed Amgen Phase 1 2004-08-01 The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.
NCT00094835 Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed Amgen Phase 1/Phase 2 2005-01-01 The purpose of this trial is: - To characterize the safety profile of motesanib when used in combination with carboplatin/paclitaxel (CP), with panitumumab or with CP and panitumumab in patients with advanced non-small cell lung cancer (NSCLC). - To establish the pharmacokinetic (PK) profile of motesanib when it is used in combination with CP, with panitumumab, or with CP and panitumumab. - To compare the paclitaxel and motesanib PK profiles when the medications are administered 30 minutes (min) or approximately 48 hours (hrs) apart. - To characterize the panitumumab and paclitaxel exposure in the combination regimens of motesanib with CP, motesanib with panitumumab, or motesanib with CP and panitumumab. - To describe the objective response rate (ORR) in each dose cohort. - To measure the immunogenicity of panitumumab in patients administered motesanib with panitumumab and motesanib with CP and panitumumab.
NCT00101894 Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer Completed Amgen Phase 1 2004-12-01 The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with either FOLFIRI or FOLFOX4 chemotherapy regimens. This is a Phase 1b clinical study.
NCT00101907 Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer Terminated Amgen Phase 1 2004-12-01 The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with gemcitabine and cisplatin chemotherapy. This is a Phase 1b clinical study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for panitumumab

Condition Name

Condition Name for panitumumab
Intervention Trials
Colorectal Cancer 44
Metastatic Colorectal Cancer 41
Colon Cancer 11
Head and Neck Cancer 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for panitumumab
Intervention Trials
Colorectal Neoplasms 117
Adenocarcinoma 20
Carcinoma, Squamous Cell 19
Head and Neck Neoplasms 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for panitumumab

Trials by Country

Trials by Country for panitumumab
Location Trials
United States 290
Spain 50
Germany 39
Canada 26
Netherlands 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for panitumumab
Location Trials
California 19
North Carolina 17
Texas 13
Tennessee 13
Pennsylvania 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for panitumumab

Clinical Trial Phase

Clinical Trial Phase for panitumumab
Clinical Trial Phase Trials
Phase 4 1
Phase 3 24
Phase 2 137
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for panitumumab
Clinical Trial Phase Trials
Completed 69
Recruiting 40
Active, not recruiting 28
[disabled in preview] 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for panitumumab

Sponsor Name

Sponsor Name for panitumumab
Sponsor Trials
Amgen 91
National Cancer Institute (NCI) 17
AIO-Studien-gGmbH 6
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for panitumumab
Sponsor Trials
Other 203
Industry 151
NIH 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
AstraZeneca
McKinsey
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.